GVAX leukemia vaccine gives encouraging results

hodgkins-histopathology.jpg

BioSante Pharmaceuticals is announcing that its GVAX Leukemia Vaccine either severely reduces or completely eliminates cancer cells remaining in some patients with chronic myeloid leukemia (CML) who have been on Gleevec for a year or longer.

Although Gleevec is a life-saver for thousands of CML patients, it generally does not clear the patient's body of all cancer cells. Consequently, should the patient stop taking Gleevec, relapse is likely.

Nineteen CML patients on Gleevec received BioSante's GVAX Leukemia vaccine (a statistically insignificant cohort) in a series of four vaccinations, and in seven patients, their cancer was undetectable.

By Ross Bonander

Source: MedicalNewsToday

LymphomaInfo Social